
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Clindamycin and Benzoyl Peroxide (BenzaClin)
Methylprednisolone Sodium Succinate (A-Methapred)
Triamcinolone Diacetate (Aristocort)
Fluticasone Propionate (Cutivate)
More Atopic Dermatitis






